September 28, 2023

Contributions to Women's Healthcare andDevelopment Pipeline in the Obstetrics andGynecology Field
Presentation for Investors
Securities code : 4886 (TSE)
ASKA Pharmaceutical Holdings Co., Ltd.

Forward Looking Statement
 The forward-looking statements contained in this presentation are based on the Company’s

assumptions and beliefs in the light of information currently available to it and involves known
and unknown risks and uncertainties.

 Accordingly, there is a possibility that actual results and development programs may differ

largely from these forecasts, due to a variety of factors.

 Thisreport contains information on Pharmaceuticals Products (including those underdevelopment), and the content of this report is not intended for medical promotion or medical
advice.

 This translation is provided solely as a reference material. In the case of any discrepancy

between the two versions, the original Japanese version shall prevail.

2

Introduction

Sohta Yamaguchi,

Senior Managing Member of the Board of Directors, Representative Director

ASKA Pharmaceutical Holdings Co., Ltd.

We strive to empower women to reach their full potential
and build a society where they can thrive and succeed.
Women's empowerment, being promoted as a national initiative, isclosely related to women's health. We believe that We cansignificantly contribute to women's health as it is one of ourmaterial issues.

4

Contributions to Women's Healthcare

Maiko Mori,

Member of the Board of Directors, Executive Corporate Officer

ASKA Pharmaceutical Holdings Co., Ltd.

Estrogen Production and Women-specific Diseases
at Different Stages of Women's Life
Female hormone (Estrogen)levelsInfertility
Imminent miscarriage/
premature birth
Dysmenorrhea, irregular menstruation, etc.
Menstrual problems

Menopausal
disordersEndometriosis, uterine fibroids, etc.

Cancer specific to women
Other diseases that are more likely to occur in womenAge(Early)childhood... 20 years old

Puberty

30 years old

40 years old

Sexual maturity

50 years old

60 years old

Menopause

70 years old...

Old age

ASKA Pharmaceutical, with 100 years of experience in endocrine hormones,
can offer valuable contributions in various areas.
Compiled by Health Lab Mint⁺ for Women's health6

Increase in the Number of Menstrual Cycles due to Changes
in Life Events
Women today experience their first menstruation earlier, tend to marry later, and experience fewer childbirths than women in past generations.
The increase in the number of menstrual cycles (MCs) experienced in women's lifetime is considered a factor for the increase in dysmenorrhea
and other menstrual problems.

Number of MCs experienced by
women today

450
Number of lifetime childbirths: Approx. 2

Menstrual periods of women today
Age: 10

20

30

40

Number of lifetime MCs: Approx.

Number of MCs experienced by
women in past generations
Number of lifetime MCs: Approx.

50

Number of lifetime childbirths: Approx.

5■ Period before menarche ■ Period with menstruation
Amenorrheic period due to pregnancy, childbirth or breast-feeding

Menstrual periods of women in past generations
Age: 10

20

30

40

■ Period before menarche ■ Period with menstruation
Amenorrheic period due to pregnancy, childbirth or breast-feeding

Modified from source: Short RV: Rroc. R. Soc. Lond B. Biol. Sci. 1976; 195, 3-24.

7Changes in the Environment Surrounding Women (Examples)
Changes in the politicalenvironment

Changes in the social
environment

Changes in the technologicalenvironment

 Establishment of the Headquarters
for Creating a Society in which All
Women Shine in the Cabinet
Secretariat, and formulation of the
Women's Version of the
Framework Policy

 Increase in the number of female
employees and promotion of
women to managerial positions
through promotion of women's
activities

 Development of pharmaceuticals
and advances in medical
technology related to diseases
specific to women, such astreatment of dysmenorrhea andinfertility

 Establishment of gynecologyspecific disease treatment andmanagement fee, and insurance
coverage of infertility treatment

 Increased awareness of healthliteracy through increased
attention to women's specifichealth issues and increased
exposure in the media and social
media, etc.

 Changes in access to medical care,including improved access tohealth information and expansionof online medical care due to thewidespread use of the Internet

Obstetrics and Gynecology(Ob/Gyn) market is expanding in response
to various changes in the environment surrounding women.
Ob/Gyn market in 2010: 49.5 billion yen*1 ➡ Ob/Gyn market in 2025 (forecast): 94.5 billion yen*2*1 Fuji Keizai Corporation 2018-2019 Ethical Drugs Databook No.4 All rights reserved.
*2 Fuji Keizai Corporation, “Trend Analysis and Future Forecast of Obstetrics and Gynecology Related Markets
Attracting Attention through Insurance Coverage," All rights reserved.

8

The Value That ASKA Pharmaceutical Holdings Can Offer

I.

Contribution to the treatment of diseases specific to women
through pharmaceutical drugs

II. Contribution to improving health literacy about women throughMint⁺’s activities
III. Contribution to the pharmaceutical peripheral field by utilizing
Femtech9

Our Ob/Gyn Pharmaceutical Products by Life Stage
Early
childhood

Puberty

Sexual maturity

Oral contraception

Drospirenone (LF111)

Iron deficiency
anemiaRiona (Co-Pro* )STD/infection
Uterine fibroids
Endometriosis
Dysmenorrhea
Menstrual disorder

ANGE

NORLEVORELUMINALEUPRORELIN

AKP-022

Jemina (Co-Pro)

FREWELL (AG)

DroEthiPMS/PMDD drugs

PLANOVAR

TRM-270

Menopause

Old age
HOLIN

Rapid SP Chlamydia (Co-pro*)

Imminent
miscarriage/
premature birth,labor induction

Infertility

Now on sale

Menopause

Under development

Magsent

MAGNESOL

RITODRINEATONINHMG
LUTEUMuFSH

Methylergometrine

SEXOVID

GONATROPINOur Ob/Gyn drugs
under development
LF111
AKP-022
TRM-270
Expands the lineup andcontributes to women's
healthcare* Mainly in the field of obstetrics and gynecology
10Contribute to Improving Health Literacy about Women through Mint⁺
Established in 2020 on the occasion of the100th anniversary of ASKA

Health Lab Mint+ for Women’s healthKey message
Knowing yourself, is protecting yourself

For the past 100 years, we have been
dedicated to addressing women's concerns
and their health. It is our fundamental
responsibility to spread awareness, shareaccurate information, and relieve theirworries.
Disseminating accurate information underphysician supervision improves women's
health literacy.

Web site contents- The Female Body: What You Should Know
- Mint⁺'s useful columns that add a little something extra to my daily life
- Mint⁺ for female teenagers: Know yourself* Japanese version only

Mint⁺'s activities in figures

Number of page views (PV)Monthly page views range from 400,000 to 600,000, with amaximum of around 900,000.
Health and physical education supplementary materials forhigh school students
Provided once a year starting in March 2020
Total of 640,000 copies were provided to 1,732 schools
Seminars
Including online events, a total of 7 seminars were held with a
total of 988 participants.
Social media posts
Posted 42 times on social media platform LINE and have 4,624
friends on LINE (as of August 28).

11

Contribute to the Peripheral Pharmaceutical Fields with Femtech
HealthPrevention

Testing/Diagnosis

Medical treatment

Prognosis
Sale of goods

Health check
Health data management

Predictive tools
Prevention programs

Digitalbiomarkers<Specialty Areas>
Ob/Gyn ProductLineupOnline Health Consultation

LIFEM
Literacy Improvement Tools

LIFEM, Femknowledge

Nutrition

Rapid test

ASKA Pharma Medical(Non-invasive testing)

SaMD/DTxSUSMED

Medication
information
management

Adverse effects
management
Monitoring

Telemedicine

Melody International
CVC Fund
ASKA Innovation FundContribute to women's health in the pharmaceutical peripheral areas by utilizing
Femtech, focusing on the Ob/Gyn product lineup, and entering the Around-The-Pill field.
12

Contribute to the Peripheral Pharmaceutical Fields with Femtech
Signed an agreement for joint development andmarketing of therapeutic applications in the fieldof obstetrics and gynecology.

ASKA Pharmaceutical Launches“Training Videos on Women's Health”* Japanese version only

13

Contribute to Solving Health Issues for All Kinds of Women
Early
childhood

Puberty

Sexual maturity

Menopause

Old age

Health – Mibyou* - Disease
Pharmaceuticals
Providing care for women's health during all stages of health, mibyou* and disease* Mibyou refers to a pre-symptomatic state.

14

Development Pipeline in the
Obstetrics and Gynecology Field

Masaya Takanashi,

Corporate Officer, Development Division Director

ASKA Pharmaceutical Co., Ltd.

Development Pipeline
R&D Status (as of August 2023)
Development code (generic name)Indication

Research*1

Non-clinical*1

Ph I

Ph II

Ph III

LF111 (drospirenone)
Contraception

Application

Approval

Ph IIIIII Ongoing
In prog(Option agreement)
Treatment for PMS/PMDD*2

Investigator-initiated Ph II Ongoing

AKP-022 (Relugolix combination tablet)
Uterine fibroids
Theme A / Ob/Gyn
Theme B / Ob/Gyn

Ph I/II OngoingTRM-270 (adhesion barrier)(Gastroenterology and Ob/Gyn)

Ph III ongoing

L-105 (rifaximin)
Hepatic encephalopathy (pediatrics)

Filed

Theme C / Internal Medicine

AKP-009 (ludaterone acetate)
Benign prostatic hyperplasia
AKP-017 (transnasal testosterone)
AKP-021 / mPGES-1 inhibitor agent

Ph IIa Completed*3
Preparing clinical trials*1 Details of research are not disclosed because it was non-clinical. *2 Premenstrual syndrome / premenstrual dysphoric disorder*3 After receiving the results of the additional Phase I study, we are again conducting a Phase I study to reconfirm the data.

16

LF 11117
17

LF 111 (Oral contraceptive)
What is an oral contraceptive?
In general, the term oral contraceptive refers to an oral
combination of progesterone (corpus luteum hormone) andestrogen (follicular hormone) with a contraceptive
mechanism in which the main action is ovulation inhibition.
Oral contraceptives are also referred to as OCs, the Pill,and combined oral contraceptives (COCs).

OC’s mechanism of action(1) Inhibits ovulation by inhibiting
gonadotropin secretion

Levonorgestrel-releasing IUS

Female sterilization

Inhibition ofovulation

Inhibition of gonadotrophin
secretion

Fallopiantube

VaginaOral contraceptives

Rhythm method (Ogino method, etc.)

Ovary(2) Change in characteristics
of cervical mucus

MethodCondomPituitary
gland

UterusPearl index for various methods of contraception*

Copper IUD

Hypothalamus

Oralcontraceptive*Pearl index:
Number of pregnancies (per 100 woman-years) in 100 women using the contraceptive
method for one year (13 cycles)

Male sterilization
No contraception

In ideal use*1 (%)

In typical use *2 (%)

0.3
0.2
0.6
2
0.4 - 5
0.5
0.10
85

9
0.2
0.8
18
24
0.5
0.15
85

IUS: Intrauterine system
IUD: Intrauterine device*1 Cases in which pregnancy occurred even though the selected method of contraception was usedcorrectly and continuously*2 Cases in which pregnancy occurred even though the selected method of contraception was used
(For oral contraceptives, failure rates includes cases in which the woman forgot to take them)(3) Endometrial changes
Prepared with our company’s treatment support tool18

LF 111 (Oral contraceptive)
Change in COC market over time

What are the major risks associated with COCs?

Quoted from our company’s treatment support tool

(unit: 1000 sheets)

In-house count based on Encise data. Unauthorized reproduction prohibited(Recalculated with the latest data)

4,783

5,330

5,843

6,458

7,258

Although the frequency of occurrence is low, thrombosis (a disease inwhich a blood vessel in a limb, lung, heart, brain, retina, etc. is blocked
by a blood clot) may occur as a severe life-threatening adverse
reaction.
Note: The incidence of venous thrombosis is generally about 5 cases per 100,000 persons per year in persons who do not take COCs,
but according to an overseas report, the risk increases 3.25 to 4-fold when COCs are taken. The proportion of patients withvenous thrombosis due to pregnancy is estimated to be 60 per 100,000 women per year.

Precautions before administration
2018
2018年

2019
2019年

2020
2020年

2021
2021年

(Fiscal year)

2022
2022年

The domestic market is tending to expand

Percentage of women who use OCs
in each country*
FranceCanada
Korea

33.1%
28.5%
3.3%

Germany
31.7%
United States 13.7%
Japan
2.9%

Quoted from our company’s
treatment support tool

1. Smoking
Smoking while taking oral contraceptives has been reported to increase the risk ofside effects such as venous thrombosis, pulmonary embolism, myocardial infarction,and stroke. This risk is said to increase with age (35 years or older) and smoking
volume (15 cigarettes or more per day). Therefore, persons 35 years old or older
who will be taking this drug need to stop smoking.
2. The following persons should not take oral contraceptives (*Partial excerpt)• Persons who are 35 or older and smoke 15 cigarettes or more per day
3. The following persons should consult a physician before receiving aprescription. If you have any concerns even after receiving a prescription,
consult a physician or pharmacist (*Partial excerpt)• Women aged 40 years or older• Women who smoke• Women who are obese* United Nations：Contraceptive Use by Method 2019 ”Estimated prevalence of contraceptive use among women of reproductive age (15-49 years), 2019”19

LF 111 (Oral contraceptive)
LF 111 Overview (planned)
Nonproprietary nameDrospirenone

Therapeutic category

Oral contraceptive

Indication

Contraception

Characteristics

Progesterone-only pill (POP*) with the ingredient drospirenone. Conventional oral
contraceptives contain two female hormones, estrogen and progesterone. Although thefrequency of occurrence is low, there is a risk of thrombosis due to estrogen. Since this is aprogestogen-only oral contraceptive, the risk of thrombosis can be expected to be lower.

Significance of development

Provides a new option for women who desire contraception and are not suitable
candidates for COC use for reasons of age, smoking, and obesity.

Status of overseas approval of LF 111 (drospirenone POP)LF has been approved in 54 countries throughout the world, including France (2019), Italy (2019), Germany (2021),
USA (2019), and Canada (2021).

* POP = progesterone only pill20

LF 111 (Oral contraceptive)
LF 111 Overview of Ph III
Research objectives

To evaluate the efficacy and safety of 13 cycles of LF 111 4 mg in Japanese women who
desire contraception.

Study phase

III

Study period

December 1, 2021 to September 30, 2024 Status of progress: Recruitment has ended

Planned number of subjects

260

Study design

Single-arm, open-label, uncontrolled, single-group comparison

Details of intervention

Subjects will receive one 4-mg LF111 tablet per day for the first 24 days and one LF111
placebo tablet per day for the subsequent 4 days (oral administration). Subjects will receive
13 consecutive treatment cycles, each consisting of 28 days. In the case of continuous
administration, administration will be continued up to 24 cycles.

Primary endpoint

General Pearl Index**Pearl index: Number of pregnancies (per 100 woman-years) in 100 women using
the contraceptive method for one year (13 cycles)

LF 111 Future outlook
The study is progressing smoothly, and we aim to launch the product as part of the current mid-termbusiness plan.
21

AKP-022

22
22

AKP-022 (Therapeutic agent for uterine fibroids)
Types of uterine fibroids

What are uterine fibroids?
Benign tumors that develop in the myometrium.
Estrogen is thought to cause them to grow larger.
In rare cases, uterine fibroids may become malignant.
Depending on where they form, they are classified as submucosal
fibroids, intramural fibroids, or subserosal fibroids. Fibroids are notalways solitary, and more than one may develop.

Subserosal fibroids
Rarely cause subjective
symptoms, even if they
become large.

Symptoms of uterine fibroids
Prolonged menstruation, menorrhagia, anemia, metrorrhagia, lower
abdominal pain, low back pain, infertility, pollakiuria/constipation
due to compression, etc.

Prevalence of uterine fibroids*

The prevalence is reported to be 4.5% to 68.6% depending on race
and age.
According to the population estimates in Japan, the population of
women aged 20 to 49 years in 2021 was approximately 21.8 million,
among which 6.55 million may have uterine fibroids. (On theassumption that the prevalence of uterine fibroids is 30%)

Submucosal fibroid
These are the most likely topresent with symptoms andcause menorrhagia,
metrorrhagia, infertility, etc.

Intramural fibroid
These fibroids have thehighest incidence(approximately 70%) andcan may cause
metrorrhagia or miscarriage
and premature birth.

Myometrium

Quoted from our company’s treatment support tool
* Koga, K, Fukui, M, Fujisawa, M, Suzukamo, Y. Impact of diagnosis and treatment of uterine fibroids on quality of life and labor productivity:
The Japanese online survey for uterine fibroids and quality of life (JOYFUL survey). J Obstet Gynaecol Res. 2023. https://doi.org/10.1111/jog.15758

23

AKP-022 (Therapeutic agent for uterine fibroids)
Treatment methods foruterine fibroids*1

Follow-up observation

Uterine fibroids

Follow-up
observation

If there is no symptoms and the fibroid is not large, follow-up
observation will be performed periodically without treatment.
Surgical therapy

Pharmacotherapy

NSAIDs, ironpreparations
GnRH analogues(RELUMINA), etc.

Conservative
therapy

Radical therapy

Uterinefibroidectomy

Total hysterectomy

Estimated number of patients treated with GnRH analogues*2
In-house count based on Encise data. Unauthorized reproduction prohibited
548,262
481,917406,893

Pharmacotherapy
This is a method of treating fibroids with drugs to suppress
symptoms such as menorrhagia, anemia, and menstrual pain.

GnRH analogues
Improve symptoms by reducing the production of
female hormones.
Since bone loss may occur owing to the estrogenlowering effect, these products should not be
administered for more than 6 months in principle.

Surgical therapy
Year ended March
2021

Year ended March
2022

Year ended March
2023

Surgery includes both open surgery and laparoscopic surgery.

*1 Prepared with our company’s treatment support tool
*2 Sum of estimated number of patients treated with the drugs per month, based on the actual quantity of RELUMINA + LEUPRORELIN 1.88 mg formulation

24

AKP-022 (Therapeutic agent for uterine fibroids)
Overview of AKP-022 (planned)
Nonproprietary name

Relugolix, ethinylestradiol, norethisterone acetate

Therapeutic category

GnRH antagonist

Indication

Uterine fibroids

Characteristics

These drugs combine relugolix, which inhibits the production of estradiol
and progestogen, with ethinylestradiol, which inhibits bone loss, andnorethisterone acetate, which inhibits endometrial proliferation.

Significance ofdevelopment

This drug is now under development. The relugolix in this combination
improves symptoms associated with uterine fibroids, the ethinylestradiol
keeps E2 levels within the range where symptoms of uterine fibroids are notexacerbated and menopausal symptoms (hot flashes, bone density
decreased) do not occur, and the progestogen inhibits the development of
E2-induced endometrial proliferation. Together,
these actions are expected to make long-term administration possible.
This drug represents a new option for the treatment of uterine fibroids.

Overseas approval status of AKP-022 (relugolix combination tablet)
It has been approved in 35 countries worldwide, including the United States (2021),
the United Kingdom (2021), and EU member states (2021).

Mechanism of action of relugolix
GnRH

Relugolix

Cellmembrane

GnRH
receptor

Pituitary
gland

Competitively binds to
GnRH receptors
Inhibits FSH/LH secretion
Inhibits follicular development andovulation
Inhibits E2/P4 production
Improves various symptoms ofuterine fibroids

GnRH (gonadotropin-releasing hormone), FSH (follicle-stimulating hormone), LH (luteinizing hormone), E2 (estrogen), P4 (progesterone)

25

AKP-022 (Therapeutic agent for uterine fibroids)
AKP-022 Overview of Ph I/II
Research objectives

The objective of this study is to evaluate the pharmacokinetics, pharmacodynamics, andsafety of multiple oral doses of AKP-022 or relugolix in healthy premenopausal Japanese
adult women.

Study phase

I/II

Study period

July 1, 2023 to July 31, 2024

Planned number of subjects

48

Study design

Randomized controlled, double-blind, active-control, parallel-group comparison study

Details of intervention

A total of two tablets (one tablet of AKP-022 and one tablet of relugolix placebo, or one
tablet of relugolix and one tablet of AKP-022 placebo) are orally administered once dailyfor 6 weeks. The first dose should be given within 1 to 5 days of the start of menstruation.

Primary endpoint• Pharmacokinetics: Concentration and pharmacokinetic parameters of relugolix, NET,E2, and E1• Pharmacodynamics: endocrinological tests and bone metabolism markers• Safety

AKP-022 Future outlook
We aim to provide a new treatment option and further enhance corporate value by developing andlaunching AKP-022 as a successor to RELUMINA.
26

TRM-270

27
27

TRM-270 (Adhesion Barrier)Postoperative adhesion and Adhesion Barriers
When tissues are sutured during surgery, it is normal for the tissues to join together and heal spontaneously,
but tissues of adjacent organs may adhere during the healing process. This is called postoperative adhesion.
Complications resulting from postoperative adhesions are known to include small intestinal obstruction,
secondary infertility, and chronic pelvic pain. The Adhesion Barrier is applied to the affected area after
surgery to prevent postoperative adhesion.

Market for Adhesion Barriers (in-house estimate)
The market for Adhesion Barriers is estimated to be about 14 billion yen.
It has been tending to grow in recent years.

Organ

Adhesion
BarrierOrgan

28

TRM-270 (Adhesion Barrier)Overview of TRM-270 (planned)

Nonproprietary name
Therapeutic category
Dosage form
Indication

Characteristics

Significance ofdevelopment
Configuration of

TRM-270=

Resorbable Adhesion Barrier
Adhesion Barrier
Sheet
Reduction of postoperative adhesion
It has a two-layer structure consisting of an Adhesion Barrier layer and a
support layer. The Adhesion Barrier layer is made of biodegradable
polylactic resin that is degraded and absorbed by the body. The support
layer is a gauze-like structure made of water-soluble resin, and it
reinforces the Adhesion Barrier layer, which is only a few hundred
nanometers thick and is difficult to handle. Since the support layer
dissolves in water, it does not need to be retrieved. This characteristic
can be expected to improve maneuverability during surgery.
This product offers good maneuverability while exerting an Adhesion
Barrier effect equivalent to that of existing products. It is being
developed as a medical device designed to promote ease of handling inlaparoscopic surgery and robot-assisted surgery, which have been
increasing in recent years.
Adhesion Barrier layer

Biodegradable polylactic resin+

Laparoscopic surgery
requires a membrane thatis easy to use within asmall scope.

Organ

Adhesion
Barrier

Organ

Support layer

Gauze-like structure made of watersoluble resin

With adhesion supplied by the Adhesion Barrier layer and flexibility supplied by the supporting layer,
it is expected to provide both adhesiveness and maneuverability.
29

TRM-270 (Adhesion Barrier)TRM-270 Overview of Phase III gastroenterology study
Research objectives

To evaluate the efficacy, safety and maneuverability of TRM-270 in patients undergoinglaparoscopic or robot-assisted surgery for rectal cancer.

Study phase

III

Study period

November 1, 2022 to February 28, 2025

Planned number of subjects

260

Study design

Randomized controlled, single-blind, active-control,
parallel-group comparison study

Details of intervention

At the time of the first stage of surgery, when resection of the primary focus and colostomy
are performed, resorbable Adhesion Barrier "TRM-270" or "Seprafilm" is applied under thesmall incision wound.

Primary endpoint

Incidence of adhesion in small incision wounds

TRM-270 Future outlook
In addition to the gastroenterology studies, we are preparing clinical trials in the fields of obstetrics andgynecology.

30

Development Pipeline - Summary of Characteristics
 LF111
Progesterone only oral contraceptive. Under development with the expectationof reducing the risk of thrombosis.
 AKP-022
Combines estrogen and progesterone with relugolix. Under development withthe expectation that long-term administration for 6 months or longer will bepossible.
 TRM-270
Under development with the expectation that it will be an Adhesion Barrier
with good maneuverability, with a special focus on handling in laparoscopic
surgery and robot-assisted surgery.
31

ASKA Pharmaceutical Holdings Group

Corporate Message

For a Healthy Tomorrow and Future.

Appendix

Women's Health Issues
The annual economic burden of menstrual
symptoms in Japanese women

Outpatient
visit costs

13.6%

Costs ofOTC drugs

14.5%

Work productivity loss

71.9%

DetailOutpatient visit
costs

Estimated amount

93.0 billion yen

Costs of OTC drugs 98.7 billion yen
Work productivity
loss

491.1 billion yen

Total 682.8 billion yen
OTC drugs: Over The Counter drugs

Made based on Tanaka E, Momoeda M, Osuga Y et al J Med Econ 2013; 16(11): 1255-1266

Current challenges for women's health in the workplace
Challenges in occupations with a relatively large
number of womenEx) Mental health and smoking rate increase in occupations
such as hospitality, standing work, call center, etc.
Challenges in menstruation
Ex) Loss due to presenteeism, lack of literacy, etc.
Challenges in women's specific diseases
Ex), such as the presence or absence of compatibility andgynecological examination
Challenges in pregnancy and childbirthEx) loss of career opportunities, etc.
Challenges in menopause
Ex) Balancing work and long-term care, loss of opportunities
in the workplace, etc.
Source: Ministry of Economy, Trade and Industry, Health Care Industry Division, "Women's
Health Initiatives in Health Management.

34
34

Number of Uterine Fibroids/Endometriosis/Dysmenorrhea Patients(Extended estimates from electronic receipt data, 12 months from January of each year to December of the following year)
2,500 ,000

209

228

(Million patients)

225
179

2,000 ,000

196

146

1,500 ,000

80

1,000 ,000

93

100

2021

2022

500 ,0 00

0

2020

2021

2022

Uterine fibroids
Source: JMDC Claims Database2020

endometriosis

2020

2021

2022

Dysmenorrhea
35Inquiries

Corporate Planning Department
Tel : +81-3-5484-8366e-mail : kouhou@aska-pharma.co.jp

36